ESMO 2025: potential new adjuvant option ensartinib for ALK+ NSCLC
86.4% of patients treated with ensartinib reached 24-month disease-free survival, compared to 53.5% in the placebo control arm.
Immuno
Asbestos-related cancers still prevalent in the UK
GSK’s anti-TIM-3 antibody fails in Phase III NSCLC trial
EHA 2025: Anito-cel to disrupt CAR-T market in multiple myeloma
Implementing pragmatic approaches for the patients and sites in oncology trials
ASCO25: AbbVie flexes ADC Phase I data as NSCLC market opportunity beckons
ASCO25: Roche’s Itovebi combo reduces risk of death in breast cancer by 33%
Navigating the FDA’s accelerated approval pathways for oncology drugs
